Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

被引:30
|
作者
Yang, Yue [1 ]
Keene, C. Dirk [1 ]
Peskind, Elaine R. [2 ,3 ]
Galasko, Douglas R. [4 ]
Hu, Shu-Ching [5 ]
Cudaback, Eiron [1 ]
Wilson, Angela M. [1 ]
Li, Ge [2 ]
Yu, Chang-En [6 ,7 ]
Montine, Kathleen S. [1 ]
Zhang, Jing [1 ]
Baird, Geoffrey S. [1 ,8 ]
Hyman, Bradley T. [9 ]
Montine, Thomas J. [1 ]
机构
[1] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[3] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA USA
[4] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[5] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
[6] Univ Washington, Dept Med, Seattle, WA 98195 USA
[7] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA
[8] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[9] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA
关键词
Alzheimer disease; Biomarkers; Cerebrospinal fluid; Cognitive impairment; Neurodegenerative disease; Parkinson disease; APOLIPOPROTEIN-A-I; AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM; E APOE POLYMORPHISM; TARGETED REPLACEMENT; MEMBRANE-VESICLES; MOUSE MODEL; CIRCULATING MICROPARTICLES;
D O I
10.1097/NEN.0000000000000207
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ-, and amyloid (A) (42)-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE epsilon 4/epsilon 4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level versus those in APOE epsilon 3/epsilon 3 or APOE epsilon 3/epsilon 4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. Cerebrospinal fluid apoE-positive and -amyloid (A(42))-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients versus age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.
引用
收藏
页码:672 / 687
页数:16
相关论文
共 50 条
  • [1] Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
    Gui, YaXing
    Liu, Hai
    Zhang, LiShan
    Lv, Wen
    Hu, XingYue
    ONCOTARGET, 2015, 6 (35) : 37043 - 37053
  • [2] Cerebrospinal fluid biomarkers in Alzheimer's disease, Parkinson's disease and atypical parkinsonism
    Stojmenovic, G. Mandic
    Markovic, I.
    Stojkovic, T.
    Despotovic, I.
    Lukic, M. Jecmenica
    Stefanova, E.
    Kostic, V.
    MOVEMENT DISORDERS, 2012, 27 : S386 - S386
  • [3] Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
    Irwin, David J.
    Fedler, Janel
    Coffey, Christopher S.
    Caspell-Garcia, Chelsea
    Kang, Ju Hee
    Simuni, Tanya
    Foroud, Tatiana
    Toga, Arthur W.
    Tanner, Caroline M.
    Kieburtz, Karl
    Chahine, Lana M.
    Reimer, Alyssa
    Hutten, Samantha
    Weintraub, Daniel
    Mollenhauer, Brit
    Galasko, Douglas R.
    Siderowf, Andrew
    Marek, Kenneth
    Trojanowski, John Q.
    Shaw, Leslie M.
    ANNALS OF NEUROLOGY, 2020, 88 (03) : 574 - 587
  • [4] Cerebrospinal fluid biomarkers in Parkinson disease
    Lucilla Parnetti
    Anna Castrioto
    Davide Chiasserini
    Emanuele Persichetti
    Nicola Tambasco
    Omar El-Agnaf
    Paolo Calabresi
    Nature Reviews Neurology, 2013, 9 : 131 - 140
  • [5] Cerebrospinal fluid biomarkers in Parkinson disease
    Parnetti, Lucilla
    Castrioto, Anna
    Chiasserini, Davide
    Persichetti, Emanuele
    Tambasco, Nicola
    El-Agnaf, Omar
    Calabresi, Paolo
    NATURE REVIEWS NEUROLOGY, 2013, 9 (03) : 131 - 140
  • [6] Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease
    Weinshel, Sarah
    Irwin, David J.
    Zhang, Panpan
    Weintraub, Daniel
    Shaw, Leslie M.
    Siderowf, Andrew
    Xie, Sharon X.
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (04) : 1155 - 1167
  • [7] Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease
    Isobe, C
    Murata, T
    Sato, C
    Terayama, Y
    LIFE SCIENCES, 2005, 77 (15) : 1836 - 1843
  • [8] Neurodegenerative Markers in Cerebrospinal Fluid in Parkinson Disease
    Vranova, Hana
    Mares, Jan
    Nevrly, Martin
    Kanovsky, Petr
    Stejskal, David
    NEUROLOGY, 2009, 72 (11) : A66 - A66
  • [9] Cerebrospinal fluid biomarkers of Alzheimer’s disease
    Xiaojing Sui
    Jianjun Liu
    Xifei Yang
    Neuroscience Bulletin, 2014, 30 : 233 - 242
  • [10] Alzheimer disease pathology and the cerebrospinal fluid proteome
    Loïc Dayon
    Antonio Núñez Galindo
    Jérôme Wojcik
    Ornella Cominetti
    John Corthésy
    Aikaterini Oikonomidi
    Hugues Henry
    Martin Kussmann
    Eugenia Migliavacca
    India Severin
    Gene L. Bowman
    Julius Popp
    Alzheimer's Research & Therapy, 10